Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck - 12/08/17
Abstract |
Background |
Binding of tumor-expressed programmed cell death ligand 1 (PD-L1) to the programmed cell death 1 (PD-1) surface receptor blocks T-cell activation thereby leading to immune evasion. Tumor PD-L1 expression has been associated with poor outcome in a wide variety of cancers; however, data in cutaneous squamous cell carcinoma (cSCC) are scarce and conflicting.
Objective |
To investigate the relationship of tumor PD-L1 expression with the clinicopathologic features and prognosis of cSCC.
Methods |
PD-L1 expression was analyzed by immunohistochemistry on paraffin-embedded tissue samples from 100 patients with cSCC. Cumulative/dynamic receiver operating characteristic curve was used to determine the optimal PD-L1 threshold. Kaplan-Meier estimators and Cox proportional hazards regression models were also used.
Results |
On the basis of cumulative/dynamic receiver operating characteristic curves, we defined the cut-off score for PD-L1 expression as ≥25% of tumor cells positively stained. PD-L1 expression was a significant risk factor for nodal metastasis with crude and adjusted hazard ratios of 3.39 (1.71-6.65) and 6.54 (2.28-18.78), respectively.
Limitations |
This is a retrospective study limited to cSCC of the head and neck.
Conclusion |
These findings indicate that tumor PD-L1 expression predicts increased risk for nodal metastasis in patients with cSCC.
Le texte complet de cet article est disponible en PDF.Key words : cutaneous squamous cell carcinoma, expression, immunohistochemistry, nodal metastasis, PD-L1, prognosis, tumor
Abbreviations used : CI, cSCC, cSCCHN, HR, PD-1, PD-L1, TMA
Plan
Funding sources: Supported by grants from the Plan Nacional de I+D+I 2013-2016 ISCIII (CP13/00013 and PI13/00259 to Dr García-Pedrero), PI16/00280 and Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00390) Spain, and the European Regional Development Fund. |
|
Conflicts of interest: None declared. |
|
Reprints not available from the authors. |
Vol 77 - N° 3
P. 527-533 - septembre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?